Clinical Trial Update: A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 [Phase 2]

View source ↗

Summary

Phase II study of carfilzomib in relapsed Waldenström's macroglobulinemia has completed, with results posted in April 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Carfilzomib (Kyprolis) (carfilzomib)

Snippet

Sponsor: Hackensack Meridian Health | Conditions: Waldenstrom Macroglobulinemia | Phase 2 | Status: COMPLETED | Results posted: 2022-04-13